Related Experiment Video
Updated: Aug 16, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
New treatment options for stroke prevention in atrial fibrillation
Benjamin Rhee1, Richard L Page
1Division of Cardiology, Department of Medicine, Robert A. Bruce Endowed Chair in Cardiovascular Research, University of Washington School of Medicine, Seattle 98195-6422, USA.
Insights
Atrial fibrillation (AF) treatment guidelines recommend anticoagulation to prevent stroke. However, this therapy is underused, highlighting a need for improved patient compliance and development of newer, safer anticoagulants.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation (AF) is a prevalent cardiac arrhythmia.
- Thromboembolic stroke is a major complication of AF.
- Current guidelines recommend warfarin for stroke prevention in most AF patients.
Purpose of the Study:
- To review current antithrombotic therapy for atrial fibrillation.
- To highlight underutilization of anticoagulation in AF patients.
- To discuss expanding indications and future therapeutic options.
Main Methods:
- Literature review of clinical guidelines and studies on AF anticoagulation.
- Analysis of warfarin efficacy and aspirin as an alternative.
- Discussion of challenges in current anticoagulation therapy.
Main Results:
- Warfarin is effective in reducing stroke risk in AF.
- Aspirin is less effective than warfarin, except in specific low-risk cases.
- Anticoagulation therapy for AF remains underutilized despite established benefits.
Conclusions:
- Despite guidelines, many eligible AF patients do not receive anticoagulation.
- Continuous anticoagulation is crucial, even after sinus rhythm restoration, due to silent AF.
- Development of novel anticoagulants may improve compliance and efficacy.
Abstract:
Atrial fibrillation (AF) is the most common arrhythmia requiring treatment. Its most devastating consequence is thromboembolic stroke. Therapy with warfarin is indicated in most patients, as it has been shown conclusively to reduce the risk of stroke. Aspirin is an inferior alternative except in certain low-risk patients or for patients with an absolute contraindication to warfarin. Guidelines have been published for the administration of antithrombotic therapy in AF, but many patients who are candidates for anticoagulation do not receive this therapy. Even as this therapy is under-utilized, the indication for anticoagulation is expanding. Indefinite continuation of anticoagulation should be considered in higher-risk patients despite the appearance that sinus rhythm has been restored because asymptomatic (or silent) AF occurs frequently. Newer agents that offer substantial benefit over warfarin are being developed and would enhance compliance with anticoagulation in AF if these novel therapies prove to be safe and equivalent to warfarin in efficacy.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Dysrhythmias VI: Management of Dysrhythmias
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Atherosclerosis III: Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care

